

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/560,932
Filing Date	2006-05-05
First Named Inventor	Yechezkel BARENHOLTZ
Group Art Unit: 1632	Conf. No.: 4072
Examiner Name	Not Yet Known
Attorney Docket Number	BARENHOLTZ 14

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Patent Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Kind Code* (if known)	YYYY-MM-DD		
	AA	US-4897355 A	1990-01-30	EPSTEIN et al.	
	AB	US-5334761 A	1994-08-02	GEBEYEHU et al.	
	AC	US-5659011 A	1997-08-19	J. J. WALDMANN	
	AD	US-5674908 A	1997-10-07	HACES et al.	
	AE	US-5783565 A	1998-07-21	LEE et al.	
	AF	US-6075012 A	2000-06-13	GEBEYEHU et al.	
	AG	US-6281371 A	2001-08-28	KLOESEL et al.	
	AH	US-5171678	1992-12-15	Centre National de la Recherche Scientifique (CNRS)	

U.S. PATENT APPLICATION PUBLICATIONS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Janet Epps Smith/
-----------------------	--------------------

Date
Considered

08/12/2010

* EXAMINER. Include if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation of abstract is provided. * REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/560,932
Filing Date	2006-05-05
First Named Inventor	Yechezkel BARENHOLTZ
Group Art Unit	1632 Conf. No.: 4072
Examiner Name	Not Yet Known
Attorney Docket Number	BARENHOLTZ 14

NON PATENT LITERATURE DOCUMENTS /OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AN	International Search Report mailed October 22, 2004 (corresponding PCT Appln. No. PCT/IL2004/000533).	
	AO	International Search Report mailed November 16, 2004 (corresponding PCT Appln. No. PCT/IL2004/000534).	
	AP	International Search Report mailed October 22, 2004 (corresponding PCT Appln. No. PCT/IL2004/000536).	
	AQ	Australian Patent Office Examination Report mailed June 30, 2006 (corresponding Singapore Application No. SG200508078-3).	
	AR	F. BRUNEL et al., "Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine", <u>Vaccine</u> , Vol. 17, pages 2192-2203, 1999.	
	AS	K. EWERT et al., "Efficient Synthesis and Cell-Transfection Properties of a New Multivalent Cationic Lipid for Nonviral Gene Delivery", <u>J. Med. Chem.</u> , Vol. 45, pages 5023-5029, 2002.	
	AT	P. L. FELGNER et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 84, pages 7413-7417, November 1987.	
	AU	X. GAO et al., "A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells", <u>Biochim. Biophys. Acta</u> , Vol. 179, pages 280-285, 1999.	
	AV	B. GUY et al., "Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine", <u>Vaccine</u> , Vol. 19, pages 1794-1805, 2001.	
	AW	M. A. ILIES et al., "Recent developments in cationic lipid-mediated gene delivery and gene therapy", <u>Expert Opin. Ther. Patents</u> , Vol. 11, No. 11, pages 1729-1752, 2001.	
	AX	K. M. LIMA et al., "Comparison of different delivery systems of vaccination for the induction of protection against tuberculosis in mice", <u>Vaccine</u> , Vol. 19, pages 3518-3525, 2001.	
	AY	A. D. MILLER, "Cationic Liposomes for Gene Therapy", <u>Chem. Int. Ed. Eng.</u> , Vol. 37, pages 1768-1785, 1987.	
	AZ	T. NAKANISHI et al., "Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins", <u>J. Controlled Release</u> , Vol. 61, pages 233-240, 1999.	
	BA	M. SAMINATHAN et al., "Ionic and Structural Specificity Effects of Natural and Synthetic Polyamines on the Aggregation and Resolubilization of Single-, Double-, and Triple-stranded DNA", <u>Biochemistry</u> , Vol. 38, pages 3821-3830, 1999.	

Examiner
Signature

/Janet Epps Smith/

Date
Considered

08/12/2010

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./